Generating 3D Spheres and 2D Air-Liquid Interface Cultures of Human Induced Pluripotent Stem Cell-Derived Type 2 Alveolar Epithelial Cells.


Journal

Journal of visualized experiments : JoVE
ISSN: 1940-087X
Titre abrégé: J Vis Exp
Pays: United States
ID NLM: 101313252

Informations de publication

Date de publication:
15 04 2022
Historique:
entrez: 2 5 2022
pubmed: 3 5 2022
medline: 6 5 2022
Statut: epublish

Résumé

In the lung, the alveolar epithelium is a physical barrier from environmental stimuli and plays an essential role in homeostasis and disease. Type 2 alveolar epithelial cells (AT2s) are the facultative progenitors of the distal lung epithelium. Dysfunction and injury of AT2s can result from and contribute to various lung diseases. Improved understanding of AT2 biology is, thus, critical for understanding lung biology and disease; however, primary human AT2s are generally difficult to isolate and limited in supply. To overcome these limitations, human induced pluripotent stem cell (iPSC)-derived type 2 alveolar epithelial cells (iAT2s) can be generated through a directed differentiation protocol that recapitulates in vivo lung development. iAT2s grow in feeder-free conditions, share a transcriptomic program with human adult primary AT2s, and execute key functions of AT2s such as production, packaging, and secretion of surfactant. This protocol details the methods for maintaining self-renewing iAT2s through serial passaging in three-dimensional (3D) culture or adapting iAT2s to air-liquid interface (ALI) culture. A single-cell suspension of iAT2s is generated before plating in 3D solubilized basement membrane matrix (hereafter referred to as "matrix"), where they self-assemble into monolayered epithelial spheres. iAT2s in 3D culture can be serially dissociated into single-cell suspensions to be passaged or plated in 2D ALI culture. In ALI culture, iAT2s form a polarized monolayer with the apical surface exposed to air, making this platform readily amenable to environmental exposures. Hence, this protocol generates an inexhaustible supply of iAT2s, producing upwards of 1 x 10

Identifiants

pubmed: 35499347
doi: 10.3791/63875
doi:

Substances chimiques

Pulmonary Surfactants 0

Types de publication

Journal Article Video-Audio Media Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR001430
Pays : United States
Organisme : NHLBI NIH HHS
ID : F30 HL147426
Pays : United States

Auteurs

Rhiannon B Werder (RB)

Center for Regenerative Medicine, Boston University and Boston Medical Center; The Pulmonary Center and Department of Medicine, Boston University School of Medicine; QIMR Berghofer Medical Research Institute.

Jessie Huang (J)

Center for Regenerative Medicine, Boston University and Boston Medical Center; The Pulmonary Center and Department of Medicine, Boston University School of Medicine.

Kristine M Abo (KM)

Center for Regenerative Medicine, Boston University and Boston Medical Center; The Pulmonary Center and Department of Medicine, Boston University School of Medicine.

Olivia T Hix (OT)

Center for Regenerative Medicine, Boston University and Boston Medical Center; The Pulmonary Center and Department of Medicine, Boston University School of Medicine.

Kasey Minakin (K)

Center for Regenerative Medicine, Boston University and Boston Medical Center; The Pulmonary Center and Department of Medicine, Boston University School of Medicine.

Konstantinos-Dionysios Alysandratos (KD)

Center for Regenerative Medicine, Boston University and Boston Medical Center; The Pulmonary Center and Department of Medicine, Boston University School of Medicine.

Carly Merritt (C)

Center for Regenerative Medicine, Boston University and Boston Medical Center; The Pulmonary Center and Department of Medicine, Boston University School of Medicine.

Kayleigh Berthiaume (K)

Center for Regenerative Medicine, Boston University and Boston Medical Center; The Pulmonary Center and Department of Medicine, Boston University School of Medicine.

Andrea B Alber (AB)

Center for Regenerative Medicine, Boston University and Boston Medical Center; The Pulmonary Center and Department of Medicine, Boston University School of Medicine.

Claire L Burgess (CL)

Center for Regenerative Medicine, Boston University and Boston Medical Center; The Pulmonary Center and Department of Medicine, Boston University School of Medicine.

Darrell N Kotton (DN)

Center for Regenerative Medicine, Boston University and Boston Medical Center; The Pulmonary Center and Department of Medicine, Boston University School of Medicine.

Andrew A Wilson (AA)

Center for Regenerative Medicine, Boston University and Boston Medical Center; The Pulmonary Center and Department of Medicine, Boston University School of Medicine; awilson@bu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH